VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

Advanced Therapies Week 2022 | Adapting to challenges in manufacturing cell therapies for solid tumors

Whilst chimeric antigen receptor (CAR) T-cell therapies have been successful in hematological malignancies, solid tumors remain an unmet need especially in patients with colorectal cancer. Christopher Ballas, PhD, Innovative Cellular Therapeutics, Rockville, MD, describes strategies to increase the production of CAR T-cell therapies for solid tumors. Decentralized manufacturing and automation will enable therapies to be produced in a shorter timeframe, improve quality control, and facilitate the regulatory process. However, logistics and cost are issues that still need to be addressed. This interview took place at Advanced Therapies Week 2022.

Disclosures

Christopher Ballas, PhD is an employee of Innovative Cellular Therapeutics.